-Advertisement-
-Advertisement-
Progressive Familial Intrahepatic Cholestasis

Study identifies predictors of long-term outcomes in rare liver disease
In patients with progressive familial intrahepatic cholestasis type 3 (PFIC3), specific genetic variations and their response to ursodeoxycholic acid (UDCA) therapy are critical factors that predict long-term outcomes, according to a study. Patients with ≥1 missense variation, positive canalicular expression of MDR3, and biliary phospholipid levels over 6.9% of total...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
Quizzes
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved